| NCT ID | NCT07317921 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Toronto |
| Condition | Protein Metabolism |
| Study Type | INTERVENTIONAL |
| Enrollment | 8 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-03-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 8 participants in total. It began in 2025-12-01 with a primary completion date of 2026-03-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Consuming dietary protein stimulates whole-body and muscle protein synthesis, the latter of which is typically measured using invasive primed constant infusions of stable isotopes with concurrent muscle biopsies. Alternative non-invasive methodologies have been developed (namely the indicator amino acid oxidation (IAAO) technique) to estimate the impact of protein ingestion on whole-body protein synthesis as a proxy for determining dietary protein requirements. Given that the IAAO technique is based on principles of protein metabolism which occur in the liver, it is unclear how representative the IAAO outcomes of whole-body protein synthesis is to skeletal muscle protein synthesis. Validation of the IAAO technique against gold-standard, biopsy-derived measures of muscle metabolism (i.e., muscle protein synthesis) would assist in mitigating the invasiveness of muscle physiology and nutrition research.
Eligibility Criteria
Inclusion Criteria: * Participants will be aged 18-35 years old * Participants will have a BMI within the normal range (i.e., 18.5-24.9) and waist-to-hip circumference ratio of \<0.95 for males and \<0.8 for circumference for females to ensure homogeneity of the sample population * Participants are willing to abide by the compliance rules of this study (e.g., abstain from extraneous physical activity 48h prior to session 4 * Self-reported regular menstrual cycle (25-35d) within the last 3 months (female participants) * Physical activity score of ≥24 units as measured by the Godin leisure time exercise questionnaire Exclusion Criteria: * Inability to adhere to any of the compliance rules judged by principal investigator * Self-reported regular tobacco or illicit drug use (e.g., growth hormone or testosterone) * Current use of hormonal contraceptives * Individuals with a history of allergy to local anesthetics (e.g., lidocaine)
Contact & Investigator
Daniel Moore, Ph.D
PRINCIPAL INVESTIGATOR
University of Toronto, Faculty of KPE
Frequently Asked Questions
Who can join the NCT07317921 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Protein Metabolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07317921 currently recruiting?
Yes, NCT07317921 is actively recruiting participants. Contact the research team at sabrina.barsky@utoronto.ca for enrollment information.
Where is the NCT07317921 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07317921 clinical trial?
NCT07317921 is sponsored by University of Toronto. The principal investigator is Daniel Moore, Ph.D at University of Toronto, Faculty of KPE. The trial plans to enroll 8 participants.